Want to join the conversation?
$VRTX has begun marketing cystic fibrosis drug Orkambi in the U.S. and will recognize its first net product revenue from Orkambi in 3Q15. $VRTX believes that there currently are about 8,500 patients in the U.S. who are eligible for treatment with Orkambi.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.